Bisphosphonates and esophageal cancer-A pathway through the confusion

William G. Dixon, Daniel H. Solomon

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Two recent papers that examined the association between oral bisphosphonates and the risk of esophageal cancer reported seemingly discrepant findings, despite both studies using data from the UK General Practice Research Database, from similar time periods. Each paper set out brief conclusions within their abstracts, generating two opposing impressions: that the risk of incident esophageal cancer is not significantly increased with bisphosphonate use, or that the risk is increased when bisphosphonates have been prescribed ten or more times, or for longer than 5 years. Of course, the latter conclusion was more widely reported in the popular press, and with patients arriving at the clinic wanting to discuss the reports, clinicians must be able to interpret the existing evidence correctly. In this article we discuss important methodological issues regarding the two observational studies, define areas of consensus and discrepancy, examine possible bias and confounding, and condense the results into a clinically useful summary. © 2011 Macmillan Publishers Limited. All rights reserved.
    Original languageEnglish
    Pages (from-to)369-372
    Number of pages3
    JournalNature Reviews Rheumatology
    Volume7
    Issue number6
    DOIs
    Publication statusPublished - Jun 2011

    Fingerprint

    Dive into the research topics of 'Bisphosphonates and esophageal cancer-A pathway through the confusion'. Together they form a unique fingerprint.

    Cite this